• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally

    Simply Wall St·08/08/2026 11:29:29
    语音播报

    Why ORIC Pharmaceuticals Stock Is Back in Focus After Q2 Earnings

    ORIC Pharmaceuticals (ORIC) has drawn fresh attention after reporting second quarter and first half 2026 results, with a wider net loss but an improved basic loss per share from continuing operations.

    See our latest analysis for ORIC Pharmaceuticals.

    The earnings update and recent shelf registration have come alongside strong share price momentum. ORIC Pharmaceuticals has posted a 7 day share price return of 21.95% and a 90 day share price return of 52.54%, while the 1 year total shareholder return sits at 46.10%. This suggests recent enthusiasm has built on top of already improving long term results.

    If ORIC's move has you rethinking where growth could come from next, this could be a moment to scan for other healthcare related AI opportunities using our 43 healthcare AI stocks

    After ORIC Pharmaceuticals' sharp move and a fresh shelf filing, the temptation is to chase momentum. Others may prefer to wait for a pullback. So how does the current valuation compare with those options?

    Preferred Price-to-Book Multiple of 3.7x: Is It Justified?

    With ORIC Pharmaceuticals now trading at $13.50, the stock carries a price-to-book, or P/B, ratio of 3.7x. That sits below the peer average of 4.8x but above the broader US Biotechs industry average of 2.5x, which gives mixed signals on how the market is valuing the company.

    The P/B multiple compares ORIC Pharmaceuticals' market value to its net assets on the balance sheet. For early stage biopharmaceutical companies that are still loss making and generating minimal or no revenue, investors often lean on P/B because traditional earnings based ratios such as P/E are not meaningful. A P/B of 3.7x indicates investors are willing to pay $3.70 for every $1 of book value.

    On a direct peer comparison, ORIC Pharmaceuticals looks cheaper than similar companies that trade at an average of 4.8x book value. That suggests the market is assigning a lower premium to ORIC's pipeline and balance sheet than it does to peers. However, against the broader US Biotechs industry, the 3.7x P/B is meaningfully higher than the 2.5x average. This implies investors still accept a higher than typical valuation despite the company reporting a loss of $140.351m, no revenue, and being forecast to remain unprofitable over the next 3 years. In other words, the current multiple prices in expectations that are stronger than the sector overall but more cautious than the direct peer group.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 3.7x (ABOUT RIGHT)

    However, ORIC Pharmaceuticals still faces key risks, including ongoing losses of $140.351m and the uncertainty of clinical trial outcomes for its early stage pipeline.

    Find out about the key risks to this ORIC Pharmaceuticals narrative.

    Next Steps

    If the mixed signals around ORIC Pharmaceuticals leave you unsure, this is a good time to look at the details yourself and decide quickly. Start by reviewing the 4 important warning signs

    Looking for more ORIC Pharmaceuticals style investment ideas?

    If ORIC Pharmaceuticals has you thinking more carefully about where your next opportunity could come from, do not leave it to chance. Put a few minutes into scanning focused stock shortlists so you are not reacting after the move has already happened.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.